05 de juliol 2019

Far away from blackbox medicine

Causal Inference
BIG DATA I REAL WORLD DATA EN L'ANÀLISI DE LA UTILIZACIÓ, SEGURETAT I EFECTIVITAT DE MEDICAMENTS, TECNOLOGIES I INTERVENCIONS SANITÀRIES

The main speech of a next workshop is about causal inference by Miguel Hernan. If you want to have a look at his book, you'll find it here.
Causal inference is one of the main issues that current machine learning methodologies often try to skip. Finally we do need to know the factors, the causes that produce a consequence, a disease. And for example with risk adjustment, it happens the same. The methodology has to provide a clear understanding of the factors for adjustment and weights. Otherwise it would be a blackbox.

04 de juliol 2019

On sufficiency

What Is Enough? Sufficiency, Justice, and Health

The capability approach is an alternative to welfarist and extra-welfarist approaches to health economic evaluations. Unfortunately, it is not so easy to put into practice. The chapter 15 of a book sheds some light on the issue.
The approach developed by us is based on an outcome called years of sufficient capability (YSC). Instead of focusing on the absolute gains of capability across a population (i.e., capability maximization), the YSC targets those who fall below a threshold level of sufficient capability, with the aim being to improve capability to sufficient levels for those who are “capability poor
These are the five capabilities of most importance:
Stability— “ability to feel settled and secure”
Attachment— “an ability to have love, friendship, and support”
Autonomy— “an ability to be independent”
Achievement— “an ability to achieve and progress in life”
Enjoyment— “an ability to experience enjoyment and pleasure”
However, at the end, the same question without easy answer:
 How to define a sufficient threshold of capability needs to be considered further. One approach would be to conduct qualitative research using participatory methods to assign a sufficient threshold for a given population.
Unfortunately the proposal of participatory methods and the measurement of capabilities is illusory, at least in my view.


02 de juliol 2019

Episode groupers: a crucial tool for population health management

A practical guide to episode groupers for cost-of-illness analysis in health services research

Summary of analytic components in selected episode groupers.

ProductEpisode exampleSample conceptual focusaNumber of episodesClinical settingPublic episode definitionLinked risk-adjustment approach
3M Patient-focused Episode SoftwareNot reported.• Event-based episodes per patient
• Cohort-based episodes among patients with a shared condition or characteristic
>500AllNo3M Clinical Risk Groups
Cave GrouperUrinary tract infection• Physician relative efficiency and effectiveness scores
• High-cost patient prediction
>500AllNoCCGroup MediScreen
CMS-BPCIUrinary tract infectionInpatient and post-acute care~50Inpatient, skilled nursing facility, inpatient rehabilitation facility, long-term care hospital or home health agencyYesNo
McKinsey & CompanyPerinatalPrincipal Accountable Provider>100AllYesYesb
Optum Symmetry Episode Treatment GroupsPregnancy, with delivery• Patient total cost of care by condition categories
• Provider profiling
>500AllYesOptum Symmetry Episode Risk Groups
OptumInsight Symmetry Procedure Episode GroupsRadical hysterectomy• Medical and surgical procedure cost
• Provider profiling
~200AllNoOptum Symmetry Episode Risk Groups
Prometheus AnalyticsPregnancyPotentially avoidable complications~100AllYesPrometheus Analytics risk adjustment
Medical Episode GrouperCardiac arrhythmias• Population profiling
• Provider profiling
>500AllNoDisease Staging and Diagnostic Cost Groups
Information as of January 2019 in public documentation reviewed for this article, which comprised peer-reviewed articles and Internet searches for vendor product names; sources as cited in the References list. Readers are encouraged to check those and related sources for more details and updated information on the groupers briefly summarized here.
CMS-BPCI Centers for Medicaid and Medicare Services’ Bundled Payments for Care Improvement.
aAs highlighted in public documentation primarily from vendors; this is not an exhaustive list of conceptual orientations among profiled groupers.
bNot detailed in public documentation reviewed for this article in cited sources.

25 de juny 2019

Behavioral insights

BEHAVIORAL INSIGHTS. BASIC TOOLKIT AND ETHICAL GUIDELINES FOR POLICY MAKERS

This OECD report is really helpful. It tries to provide a concret approach to behavioral insights for policy makers. It goes beyond standard nudging perspective.


24 de juny 2019

Making healthcare more human

Eric Topol on making healthcare more human 

A weekly conversation that looks at the way technology is changing our economies, societies and daily lives. Hosted by John Thornhill, innovation editor at the Financial Times.


20 de juny 2019

Pharma outlook

World Preview 2019,Outlook to 2024

If worldwide Total Prescription Drug Sales (2010-2024) increase 6,9% every year between 2019 to 2024 than somebody has to tell me the source to achieve such resources. This is the estimate of a report. I know, the report says worldwide, but it seems an expected revenue that it is really out of any budget, public and private. We'll see.

Prescription drug sales for 2010 through 2018 grew at a CAGR of +2.3%. This can be compared to the forecast annual CAGR of +6.9% for 2019 through 2024 with expected sales to reach $1.18trn. The growth rate for the prescription market in 2019 is forecast to be +2.0%, which depicts a decline in growth rate compared to 2018 (+5.0%). So far the industry has seen a major set-back with one of the biggest failures, aducanumab, which was discontinued in Phase 3 trials for Alzheimer’s disease.
Distrust fortune tellers. Nobody knows anything about the future.